Massachusetts will soon change its Medicaid payment policy to bar managed care plans from paying for seven high-cost, anti-obesity medications [...] Please Login or Become a Paid Subscriber to View this Content If you are not yet a paid subscriber, please Subscribe now For questions about subscriptions or technical assistance, please contact Reshma Eggleston at [email protected] .
But in March 2024, after clinical trial results published in November 2023 showed that semaglutide-based GLP-1s such as Novo Nordisks Wegovy can reduce cardiovascular incidents, Medicare announced that Part D plans could cover Wegovy for patients with an elevated body mass index (BMI) and established cardiovascular disease. Medicare has yet to provide an exact definition of established cardiovascular disease, so its unclear how many beneficiaries would qualify for the coverage
Tezspire was approved in 2021 as an add-on maintenance treatment for severe asthma
A true plateau means zero weight loss over an extended period
On a broader societal level, the use of GLP-1 medications for weight loss may be reinforcing the negative stigmas around fatness and being overweight that often contribute to the development of eating disorders
Metformin often supports modest weight loss and better blood sugar control, especially in people with insulin resistance or prediabetes
